Neutrophil to lymphocyte ratio and risk of neoplastic progression in patients with Barrett's esophagus

被引:10
|
作者
Peleg, Noam [1 ,2 ]
Schmilovitz-Weiss, Hemda [1 ,2 ]
Shamah, Steven [1 ,2 ]
Schwartz, Ariel [3 ]
Dotan, Iris [1 ,2 ]
Sapoznikov, Boris [1 ,2 ]
机构
[1] Rabin Med Ctr, Div Gastroenterol, Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[3] Rabin Med Ctr, Dept Pathol, Petah Tiqwa, Israel
关键词
DIAGNOSIS; MANAGEMENT; CANCER; GUIDELINES; DYSPLASIA; SURVIVAL;
D O I
10.1055/a-1292-8747
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Patient's with Barrett's esophagus (BE) are at risk of progression to esophageal adenocarcinoma (EAC). Neutrophil to lymphocyte ratio (NLR) was found to be a predictor of poor prognosis in patients with EAC; however, its performance in premalignant esophageal lesions is vague. We aimed to evaluate the utility of NLR as a predictor of histologic progression in patients with BE. Methods A prospective cohort of patients with proven BE in a tertiary referral center was retrospectively analyzed. All biopsies were reviewed by an expert gastrointestinal pathologist. The discriminatory capacity of NLR was evaluated by area under the receiver operating characteristic (AUC) curve analysis and Cox regression analysis. Results 324 patients (mean age 62.3 years, 241 [74.4%] males) were included in the final analysis. Overall, 13 patients demonstrated histologic progression to neoplasia over a mean follow-up of 3.7 years (progression risk 1.0% per year). The AUC of NLR for progression to high grade dysplasia (HGD) or EAC was 0.88 (95% confidence interval [CI] 0.83-0.96), and baseline NLR was associated with a 3-fold increase of progression to HGD and EAC during follow-up (hazard ratio [HR] 3.2, 95%CI 1.5-5.8; P <0.001). Notably, in a subgroup analysis of patients with nondysplastic BE (NDBE) at presentation, NLR was also a risk factor for histologic progression (HR 2.4, 95%CI 1.7-3.4; P <0.001). Conclusion NLR predicted histologic progression in patients with BE. Patients with NDBE and NLR above 2.4 can be considered for specific surveillance programs with shorter intervals between sessions.
引用
收藏
页码:774 / 781
页数:8
相关论文
共 50 条
  • [41] Predictors for Neoplastic Progression in Patients with Barrett Esophagus: A Prospective Cohort Study
    Sikkema, Marjolein
    Kerkhof, Marjon
    Looman, Caspar W.
    Kuipers, Ernst J.
    Siersema, Peter D.
    GASTROENTEROLOGY, 2009, 136 (05) : A158 - A158
  • [42] Prospective multicenter study on the incidence of neoplastic progression in Barrett esophagus patients
    Sikkema, Marjolein
    Kerkhof, Marjon
    Steyerberg, E. W.
    Van Dekken, Herman
    Van Vuuren, Anneke
    Bode, Willem a.
    Van Der Valk, Haris
    Bac, Dirk Jan
    Giard, Raimond
    Lesterhuis, Wilco
    Heinhuis, Robert
    Klinkenherg, Elly C.
    Meijer, Gerrit a.
    Borg, Frank T.
    Arends, Jan-Willem
    Kolkman, Jeroen. J.
    Van Baarlen, Joop
    De Vries, Richard a.
    Mulder, Andries H.
    Van Tilburg, Antonie J.
    Offerhaus, Johan
    Ten Kate, Fiebo J.
    Kusters, Johannes G.
    Kuipers, E. J.
    Siersema, Peter D.
    GASTROINTESTINAL ENDOSCOPY, 2008, 67 (05) : AB75 - AB75
  • [43] Prospective multicenter study on the incidence of neoplastic progression in Barrett esophagus patients
    Sikkema, M.
    Kerkhof, M.
    Steyerberg, E. W.
    van Dekken, H.
    van Vuuren, A. J.
    Bode, W. A.
    van der valk, H.
    Bac, D. J.
    Giard, R.
    Lesterhuis, W.
    Heinhuis, R.
    Klinkenberg, E. C.
    Meijer, G. A.
    ter Borg, F.
    Arends, J. W.
    Kolkman, J. J.
    van Baarlen, J.
    de Vries, R. A.
    Mulder, A.
    van Tilburg, A. J. P.
    Offerhaus, G. J. A.
    Ten Kate, E. J. W.
    Kusters, J. G.
    Kuipers, E. J.
    Siersema, P. D.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2009, 21 (03) : A42 - A42
  • [44] The Nuclear Receptors FXR and PXR As Early Markers in Neoplastic Progression in Patients with Barrett's Esophagus
    Van de Winkel, Anouk
    van der Laan, Luc J.
    van Zoest, Katinka P.
    Moons, Leon M.
    van Dekken, Herman
    Kuipers, Ernst J.
    GASTROENTEROLOGY, 2009, 136 (05) : A455 - A456
  • [45] Risk factors for neoplastic progression in Barrett's mucosa
    MenkePluymers, MBE
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 1996, 22 (04): : 311 - 316
  • [46] PREDICTION IN SURVEILLANCE OF BARRETT'S ESOPHAGUS: THE EFFECT OF MULTIPLE MEAUREMENTS OF BIOMARKERS ON THE ESTIMATED NEOPLASTIC PROGRESSION RISK
    Roumans, Carlijn A.
    Spaander, Manon
    Lansdorp-Vogelaar, Iris
    Biermann, Katharina
    Bruno, Marco J.
    Steyerberg, Ewout W.
    Rizopoulos, Dimitris
    GASTROENTEROLOGY, 2018, 154 (06) : S4 - S4
  • [47] External validation of a model determining risk of neoplastic progression of Barrett's esophagus in a cohort of US veterans
    Nguyen, Theresa H.
    Thrift, Aaron P.
    Ketwaroo, Gyanprakash A.
    Du, Xianglin L.
    Novelo, Luis Leon
    George, Rollin
    Rosen, Daniel G.
    El-Serag, Hashem B.
    GASTROINTESTINAL ENDOSCOPY, 2022, 95 (06) : 1113 - 1122
  • [48] Association Between Aberrant p53 Expression and Risk of Neoplastic Progression in Barrett's Esophagus
    Sanossian, Cassandra
    Cheesman, Antonio R.
    DiMaio, Christopher J.
    Kumta, Nikhil
    Polydorides, Alexandros
    Nagula, Satish
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S227 - S227
  • [49] Barrett's esophagus - Reducing the risk of progression to adenocarcinoma
    Reynolds, JC
    Waronker, M
    Pacquing, MS
    Yassin, RR
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 1999, 28 (04) : 917 - +
  • [50] RISK OF NEOPLASTIC PROGRESSION IN PATIENTS WITH LONG-SEGMENT BARRETT'S ESOPHAGUS-JAPAN MULTICENTER PROSPECTIVE COHORT STUDY
    Ishimura, Norihisa
    Matsuhashi, Nobuyuki
    Fujisaki, Junko
    Endo, Takao
    Koike, Tomoyuki
    Dobashi, Akira
    Kawada, Kenro
    Ishihara, Ryu
    Matsueda, Kazuhiro
    Mukaisho, Ken-Ichi
    Furuta, Takahisa
    Kinoshita, Yoshikazu
    Haruma, Ken
    Iishi, Hiroyasu
    Iijima, Katsunori
    GASTROINTESTINAL ENDOSCOPY, 2020, 91 (06) : AB396 - AB396